About the Client

Pharmacyclics, Inc, and Janssen Biotech, Inc, have partnered together in the development, marketing and promotion of IMBRUVICA® (ibrutinib), a recently approved, first-in-class therapy for the treatment of previously treated mantle cell lymphoma, previously treated chronic lymphocytic leukemia, and chronic lymphocytic leukemia with 17p deletion. Numerous clinical trials are underway to evaluate ibrutinib’s safety and efficacy in additional hematologic malignancies.

Click to visit our website

The Team

• Management Supervisor, SVP: Diane Vinch
• Account Group Supervisor, VP: Karyn Ruff
• Management Supervisor, VP: Tara Bernardino, MSc
• Art Director: Patrick Walsh
• Copy Writer: Lyndsay Strandell
• Senior Interface Engineer: Emma Story
• Associate Creative Director/Art, VP: Eric Hannula
• Scientific Associate, PHD: Lisa Green
• Associate Director of Technology: Carolyn Boschi
• Executive Medical Director, PHD: David Bonnyay
• Chief Digital Officer: David Cherry
• Group Creative Director, SVP: Chris Duffey
• Executive Creative Director, EVP: Diane Ohye
• Group Creative Director, SVP: George Lewis
• Associate Director of Technology: David Stein
• Director of Technology, SVP: Dino Gravato
• Project Manager: Gloria Ariza-Greve
• Art Director: Connor Delaney